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Thymidine phosphorylase (dThdPase) is an enzyme that is
involved in pyrimidine nucleoside metabolism. It catalyses the
reversible phosphorolysis of thymidine, deoxyuridine and their
analogues to their respective bases and 2-deoxyribose-1-phosphate
(Cook et al, 1979; Eda et al, 1993). Using dThdPase, 5¢-deoxy-5-
fluorouridine (5¢-DFUR), a prodrug of 5-fluorouracil (5-FU), is
converted to 5-FU which is an anti-tumour drug used to treat a
variety of neoplastic diseases such as gastric carcinoma (Ishitsuka
et al, 1980; Miwa et al, 1987). As the expression of dThdPase is
higher in tumours than in normal tissue (Kono et al, 1983; Nio et
al, 1992), 5¢-DFUR is used for several kinds of human tumours.
However, to ensure suitable administration of 5¢-DFUR, it is
important to select the patients whose tumour tissue shows a much
higher content of dThdPase.
Recently, it was reported that dThdPase is identical to platelet-
derived endothelial cell growth factor (PD-ECGF) (Ishikawa et al,
1989; Furukawa et al, 1992). PD-ECGF stimulates chemotaxis of
endothelial cells in vitro and has an angiogenic activity in vivo
(Ishikawa et al, 1989; Miyazono et al, 1987). Experimental
evidence has shown that angiogenesis plays a significant role in
tumour growth and metastasis (Folkman, 1990; Folkman and
Klagsbrun, 1987).
Thus far, the expression of dThdPase has been examined in a
variety of types of neoplasm by immunohistochemistry, and its
relations with prognosis, distant metastasis and disease progression
have been discussed (Maeda et al, 1996; Takebayashi et al.,
1996a). However, neither the characteristics of tumours with much
higher protein levels of dThdPase nor the regulatory mechanisms
of dThdPase production in gastric cancer has been clarified.
In this study, in order to quantitatively assess the clinicopatho-
logical factors related to dThdPase and to elucidate the mecha-
nisms of dThdPase induction, the intratumoural protein levels of
dThdPase were determined by enzyme-linked immunosorbent
assay (ELISA) in 75 gastric carcinoma tissues. For localization of
dThdPase in cancer tissue, immunohistochemical studies were
also performed.
MATERIALS AND METHODS
Patients
Tissue samples were obtained from 75 gastric cancer patients who
underwent surgical resection at Kanagawa Cancer Center between
August 1996 and February 1998. All patients were primary, except
one patient with recurrent nodules of peritoneal dissemination.
Classification of the resected gastric cancer tissues and patho-
logical diagnosis were carried out according to the General
Rules for the Gastric Cancer Study in Surgery and Pathology
in Japan (Japanese Research Society for Gastric Cancer, 1995).
Macroscopic types, based on Borrmann￿s classification, were as
follows:
¥ type 0 — early gastric cancer
¥ types 1, 2, 3 and 4 — Borrmann types I, II, III and IV advanced
gastric cancer
¥ type 5 — unclassified advanced gastric cancer (Japanese
Research Society for Gastric Cancer, 1995).
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Summary Previous studies demonstrated that the immunohistochemical expression of thymidine phosphorylase (dThdPase) was related
with distant metastasis and disease progression. In this study we investigated the production of dThdPase/platelet-derived endothelial cell
growth factor in gastric cancer quantitatively. In a total of 75 tumour tissues and 60 normal gastric mucosa specimens, dThdPase protein
concentrations were determined by ELISA. The amount of dThdPase was significantly higher in the tumour tissue than in the normal tissue.
Intratumoural dThdPase concentrations were significantly higher in Borrmann types I and II macroscopically, in poorly differentiated and solid
type histologically, in the medullary type of the tumour stroma, and in the tumour-invading serosa. In the medullary type of the amount of
tumour stroma, protein levels of dThdPase were positively correlated with the vertical diameter of the tumour (r = 0.580, P = 0.019). By
immunohistochemical study, dThdPase expression on tumour cells was observed in all seven specimens with high dThdPase protein levels,
but not in all 14 cases with low dThdPase protein levels (P < 0.05). In summary, these data indicated that dThdPase is up-regulated in
advanced solid types of gastric cancer, suggesting that dThdPase production in carcinoma cells might be induced by the microenvironment.
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Primary tumour tissues in 74 primary gastric cancer patients and a
disseminated nodule in one recurrent patient were obtained during
surgery. Normal gastric mucosa specimens were also resected in
60 primary tumour patients. Tissue samples were immediately
frozen after the removal and stored at —80°C until processing. The
frozen tissue samples were homogenized with phosphate-buffered
saline (PBS) and centrifuged at 8000 g for 20 min. The super-
natants were then used for the detection of the amount of
dThdPase. The protein content was determined by DC protein
assay (Bio-Rad, Hercules, CA, USA).
dThdPase assay
The amount of dThdPase protein was quantitated with ELISA as
described (Nishida et al, 1996). Ninety-six-well microtiter plates
were coated with 10 mg/ml of anti-human dThdPase monoclonal
antibody 104B (Nippon Roche Research Center, Kanagawa,
Japan) in PBS solution and then incubated with blocking solution
containing skim milk. This antibody was prepared by using as an
antigen human dThdPase purified from human colon cancer
HCT116. The characterization of the antibody has been reported
previously (Nishida et al, 1996). For the assay, 50 ml of properly
diluted samples and serially diluted dThdPase (standards) were
added to the wells and incubated for 2 h at 37°C, then washed with
0.05% Tween 20 in PBS and incubated with dThdPase monoclonal
antibody 232-1. After washing the wells four times, 50 ml of anti-
mouse IgG antiserum conjugated with peroxidase was added to the
wells and incubated for 1 h at room temperature. Wells were
washed four times, and then the enzyme reaction was carried out at
37°C for 1 h with a substrate solution containing 3,3¢,5,5¢-tetra-
methylbenzidine (TMB) and hydrogen peroxide (TMB microwell
peroxidase substrate system, KPL). The reaction was stopped
by adding phosphoric acid and the absorbance at 450 nm was
measured with a microplate reader. dThdPase contents were
adjusted by the whole protein concentrations and expressed as
unit/mg protein (U/mg protein).
Immunohistochemistry
For localization of dThdPase in gastric cancer tissue, immuno-
histochemical studies were performed on deparaffinized sections
by the peroxidase-labelled streptavidin—biotin method using
anti-dThdPase monoclonal antibody 654-1 (Nishida et al, 1996),
provided by Nippon Roche Research Center, in seven tumour
specimens with extremely high protein levels of dThdPase
(† 200 U/mg protein) and 14 tumour tissues with low protein
levels of dThdPase (< 70 U/mg protein). The clinicopathological
characteristics of these cases are shown in Table 1.
Briefly, the sections were treated with skim milk in PBS at room
temperature and incubated with the anti-dThdPase mouse mono-
clonal antibody (1 mg/ml) overnight at 4°C. After washing with
PBS, the sections were further incubated with biotinylated anti-
mouse IgG for 30 min at room temperature. Thereafter, the
sections were treated with 1 mg/ml periodic acid in PBS for
10 min to block endogenous peroxidase activity. After being
washed again with PBS, the sections were incubated with
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Table 1 Clinicopathological characteristics in 21 cases selected for immunohistochemistry
Case Macroscopic  Vertical  Histological type Amount of  Depth of Venous dThdPase contents
type diameter (cm) tumour stroma invasion invasion (U/mg protein)
High levels of dThdPase protein (³ 200 U/mg protein)
1 1 2.2 Poorly differentiated and solid Medullary SE Positive 210.0
2 3 2.5 Moderately differentiated tubular Medullary SE Negative 217.4
3 3 1.4 Mucinous Intermediate SE Negative 262.5
4 1 1.0 Moderately differentiated tubular Intermediate SE Positive 411.9
5 2 1.4 Moderately differentiated tubular Medullary SI Negative 210.3
6 2 1.0 Poorly differentiated and solid Medullary SE Negative 310.8
7a 2 2.0 Poorly differentiated and solid Medullary SE Positive 459.2
Low levels of dThdPase protein (< 70 U/mg protein)
8 4 2.3 Poorly differentiated and non-solid Scirrhous SE Negative 37.2
9 4 1.2 Poorly differentiated and non-solid Scirrhous SE Positive 65.9
10b 4 2.0 Poorly differentiated and non-solid Scirrhous SE Negative 42.4
11 4 1.6 Poorly differentiated and non-solid Scirrhous SE Negative 69.9
12 4 2.3 Mucinous Scirrhous SE Positive 58.3
13 4 1.0 Poorly differentiated and non-solid Scirrhous SE Negative 33.1
14 4 2.1 Poorly differentiated and non-solid Scirrhous SE Positive 56.9
15 3 1.8 Poorly differentiated and solid Intermediate SE Negative 53.0
16 2 0.8 Poorly differentiated and solid Intermediate SE Positive 38.6
17 3 1.4 Mucinous Intermediate SE Positive 67.5
18 3 1.2 Moderately differentiated tubular Intermediate SE Positive 57.4
19 0 ≤ 0.5 Moderately differentiated tubular Medullary M Negative 48.7
20 0 ≤ 0.5 Well differentiated tubular Medullary M Negative 68.6
21 0 ≤ 0.5 Moderately differentiated Medullary SM Negative 62.3
aImmunohistochemical findings in case 7, shown in Figure 4. bImmunohistochemical findings in case 10, shown in Figure 5. M, mucosal neoplastic involvement;
SM, submucosal neoplastic involvement; SE, serosal involvement; SI, serosal involvement with directly infiltrating other organs beyond serosa. Macroscopic
types are based on Borrmann’s classification as follows: type O, early gastric cancer; types 1, 2, 3 and 4, Borrmann’s types I, II, III and IV advanced gastric
cancer; type 5, unclassified advanced gastric cancer.avidin—biotin complex (Vectastain ABC kit: Vector, Burlingame,
CA, USA) for 30 min at room temperature and developed with
1 mg/ml diaminobenzidine tetrahydrochloride in PBS containing
0.03% hydrogen peroxide. The sections were also counterstained
with methyl green and mounted.
We decided that the tumour cells should be regarded as
dThdPase-positive when more than 50% of the tumour cells were
stained. Infiltrating cells invading tumour tissue were also
regarded as dThdPase-positive when more than 50% of the infil-
trating cells were stained.
Statistical analysis
Comparisons between the two groups were performed by paired
and unpaired Student￿s t-test and c2 method. For more than three
groups, one-way analysis of variance (ANOVA) and Duncan￿s
multiple range test were used. Correlations were evaluated by
Spearman￿s test. P < 0.05 was considered to indicate statistical
significance. Data were expressed as mean ± SD.
RESULTS
The amount of dThdPase was significantly higher in the tumour
tissue than in the normal tissue by paired Student￿s t-test
(89.3 ± 86.6 U/mg protein, 36.8 ± 24.3 U/mg protein, respectively).
The tumour—normal (T/N) ratios of dThdPase contents were more
than 1.0 in 52 cases (86.7%), more than 2.0 in 29 cases (48.3%) and
more than 3.0 in 16 cases (26.7%) of 60 cases examined (Figure 1).
Intratumoural dThdPase concentrations are shown in Table 2.
dThdPase levels were significantly associated with macroscopic
types, microscopic types and the amount of tumour stroma. In the
macroscopic type, amounts of dThdPase were significantly higher
in type 1 than in types 0, 3, 4 and 5, while those in type 2 were
greater than in types 0, 4 and 5. In the microscopic type, poorly
differentiated and solid type had significantly higher concentra-
tions of dThdPase than well or moderately differentiated tubular
type, poorly differentiated and non-solid type, and signet ring cell
type. In the amount of tumour stroma, dThdPase levels were
significantly higher in the medullary type than in other types
(Figure 2). Although there was no significant difference among
the depth of invasion by ANOVA, dThdPase protein levels in
cases with serosal invasion (n = 31) were significantly higher
than in cases without serosal invasion (n = 43) (106.9 ± 98.9 and
67.2 ± 33.1, respectively, P < 0.05). There were no significant
correlations between dThdPase and age, lymph node metastasis,
peritoneal dissemination, lymphatic invasion, venous invasion
and stages.
In the medullary type of the amount of tumour stroma, protein
levels of dThdPase were positively correlated with the vertical
diameter of the tumour (Table 3, Figure 3). The amounts of
dThdPase were not significantly correlated with depth of invasion
and the horizontal diameter of the tumour (Table 3).
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Figure 1 Distribution of tumour–normal (T/N) ratio of thymidine
phosphorylase protein concentrations determined by ELISA
Table 2 Intratumoral concentrations of dThdPase
dThdPase Statistics
(U/mg protein)
Sex NS
Male (n = 51) 99.6 ± 91.0
Female (n = 24) 73.5 ± 47.9
Macroscopic type a P < 0.05
0 (Early gastric cancer, n = 16) 63.3 ± 31.2
1 (n = 5) 181.9 ± 141.7
2 (n = 8) 164.0 ± 154.0
3 (n = 14) 103.0 ± 68.0
4 (n = 16) 60.2 ± 31.1
5 (Unclassified, n = 15) 69.3 ± 33.8
Histological type P < 0.05
Papillary (n = 1) 56.4
Well differentiated tubular (n = 8) 58.8 ± 24.7
Moderately differentiated tubular (n = 18) 106.6 ± 94.8
Poorly differentiated and solid (n = 10) 172.3 ± 129.6
Poorly differentiated and non-solid (n = 24) 60.8 ± 32.3
Signet ring cell (n = 6) 63.2 ± 22.3
Mucinous (n = 7) 102.9 ± 76.2
Adenosquamous (n = 1) 117.7
Lymph node metastasis NS
Negative (n = 25) 70.8 ± 40.7
Positive (n = 49) 100.2 ± 93.3
Peritoneal dissemination NS
Negative (n = 58) 97.1 ± 85.8
Positive (n = 17) 71.2 ± 55.2
Depth of invasion NS
Mucosa (n = 7) 45.8 ± 21.6
Submucosa (n = 9) 78.1 ± 30.6
Muscularis propria (n = 11) 75.0 ± 40.2
Subserosa (n = 4) 58.3 ± 20.2
Serosa exposed (n = 38) 106.0 ± 102.8
Serosa infiltrating (n = 5) 114.0 ± 69.9
Lymphatic invasion NS
Negative (n = 25) 91.9 ± 98.3
Positive (n = 48) 89.3 ± 71.4
Venous invasion NS
Negative (n = 48) 81.9 ± 63.4
Positive (n = 24) 108.3 ± 108.5
Amount of stroma P < 0.05
Medullary (n = 17) 145.4 ± 111.6
Intermediate (n = 23) 96.0 ± 86.3
Scirrhous (n = 28) 59.6 ± 27.1
Stage NS
Ia (n = 15) 60.7 ± 30.1
Ib (n = 7) 85.8 ± 44.8
II (n = 7) 73.5 ± 42.7
IIIa (n = 15) 117.2 ± 106.5
IIIb (n = 11) 135.2 ± 128.2
IVa (n = 4) 54.4 ± 31.8
IVb (n = 15) 79.4 ± 62.7
Recurrence (n = 1) 165.3
aSee footnote to Table 1 for classification.The normal gastric mucosal cells were not stained with anti-
dThdPase antibody. Unequivocal staining of cytoplasm and
nuclear compartment were observed in most of the carcinoma cells
in all seven specimens with high dThdPase protein levels (Table 4,
Figure 4), while in all cases with low dThdPase levels, most of the
tumour cells were not stained (Table 4, Figure 5); there was a
significant difference in the staining of carcinoma cells between
these two groups by c2 test. dThdPase expression was often
observed in the tumour cells invading vessels (Figure 6). On the
other hand, the expression on macrophage-like cells on the stromal
cells was observed in all 14 cases with low dThdPase levels and in
four of seven cases with high levels (Table 4, Figures 4 and 5).
DISCUSSION
dThdPase has been reported to be increased in a variety of types
of tumours (Kono et al, 1983; Nio et al, 1992). Carcinomas in
the stomach contained higher amounts of dThdPase than non-
neoplastic gastric mucosa (Yoshimura et al, 1990). As 5¢-DFUR
is metabolized to 5-FU by dThdPase (Miwa et al, 1987; Ishikawa
et al, 1989), 5¢-DFUR has been expected to be more specific
and effective in tumour tissue than 5-FU. In this study, we
demonstrated that dThdPase levels were increased in tumour
tissue compared with those in normal mucosa in 86.7% of primary
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Table 3 Correlations between depth of invasion and maximal diameters in
horizontal and vertical sections
rP -value
All cases (n = 74)
Depth of invasion 0.101 0.404
Horizontal diameter –0.04 0.973
Vertical diameter 0.146 0.226
Medullary type (n = 17)
Depth of invasion 0.468 0.058
Horizontal diameter 0.310 0.227
Vertical diameter 0.580 0.019
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Figure 2 dThdPase protein levels and the amount of stroma in cancer tissue
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Figure 3 dThdPase protein levels and the vertical diameter in the medullary type of the amount of stromagastric cancer patients; moreover, 48.3% of patients had more than
two times the level of dThdPase in tumour tissue than appears in
normal tissue. Higher T/N ratios of dThdPase activity are prefer-
able in patients who are treated with 5¢-DFUR, because of the
probable high cytotoxicity against tumour tissue and the low
toxicity against normal tissue. Determination of tissue levels of
dThdPase would be useful for selecting the most appropriate
patients for 5¢-DFUR treatment.
To evaluate the characteristics of gastric carcinoma with high
protein levels of dThdPase, clinicopathological findings were
analysed. Our data demonstrated that dThdPase protein levels were
increased in Borrmann types I and II macroscopically, in poorly
differentiated and solid type histologically, in the medullary type of
the tumour stroma, and in the tumour-invading serosa. In the
medullary type of the amount of tumour stroma, dThdPase was
positively correlated with the vertical diameter of the tumour.
These data indicated that dThdPase is increased in advanced solid
tumours in gastric cancer. Vascularization of advanced solid
tumours is known to be poor and disordered, leading to insufficient
perfusion and diffusion of nutrients to areas of the tumour (Griffiths
and Stratford, 1997). This is thought to be a major reason for the
existence of hypoxia, glucose depletion and low pH within solid
tumours (Griffiths and Stratford, 1997). It was indicated that the
expression of dThdPase was induced by hypoxia and low pH in
human breast tumour cells (Griffiths et al, 1997). These mecha-
nisms might be involved in higher amounts of dThdPase observed
in advanced solid tumours in gastric cancer.
Previously, only two investigators evaluated the expression of
dThdPase in gastric cancer by immunohistochemistry (Maeda et al,
1996; Takebayashi et al, 1996a). It was demonstrated that
dThdPase expression was detected in 42% of gastric cancer and
observed in gastric carcinoma cells but not in normal mucosa
(Takebayashi et al, 1996a). It was also indicated that dThdPase
expression was detected in 60.8% of gastric cancer and mainly
observed in tumour cells but also sometimes in endothelial cells,
lymphocytes or macrophages invaded into tumour stroma (Maeda
et al, 1996). On the other hand, in colon and breast cancer, the
production of dThdPase by infiltrating cells has been investigated
and found to contribute to overall tumour levels (Takebayashi et al,
1996b). As shown in this study, dThdPase expression was observed
in not only tumour cells but also stromal cells, suggesting that
production in both of these cells would contribute to the overall
dThdPase protein content in gastric cancer tissue. Moreover, the
expression of dThdPase in tumour cells was mostly observed in the
advanced solid type with high dThdPase protein content. These
data support our hypothesis that dThdPase production in carcinoma
cells might be induced by the microenvironment.
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Table 4 Site of production and the concentrations of dThdPase
Tumour cells Stromal cells
High contents (³ 200 U/mg protein) 7/7 4/7
Medullary (n = 5) 5/5 2/5
Intermediate (n = 2) 2/2 2/2
Low contents (< 70 U/mg protein) 0/14 14/14
Medullary (n = 3)a 0/3 3/3
Intermediate (n = 4) 0/4 4/4
Scirrhous (n = 7) 0/7 7/7
aAll cases were early gastric cancer.
Figure 4 Immunohistochemical staining for dThdPase (original
magnification ´ 50). There is a strong staining of cytoplasm and nuclear
compartment of the tumour cells
Figure 5 Immunohistochemical staining for dThdPase (original
magnification ´ 100). There is a strong staining in the stromal cells, but not in
the tumour cells
Figure 6 Immunohistochemical staining for dThdPase in cancer cells
invading vessels (original magnification ´ 40). There is a strong staining of
tumour cells inside the vesselsdThdPase in gastric cancer tissue was reported to be related to
progression, metastasis and prognosis (Takebayashi et al, 1996a).
It has also been indicated that dThdPase is associated with venous
invasion, intratumoural microvessel count and hepatic metastasis,
although that is not an independent prognostic factor in gastric
cancer (Maeda et al, 1996). Our data did not indicate the relation
of dThdPase levels with venous invasion and metastasis; however,
dThdPase expression was often observed in the tumour cells
invading vessels. It is likely that the evaluation by tumour cell
staining observed by immunohistochemistry is different from the
overall protein levels. dThdPase was not reported to be correlated
with microvessel count in breast cancer (Fox et al, 1996). Fox et al
(1996) suggested that dThdPase possibly involves in the early
phase of angiogenesis as dThdPase is not mitogenic but chemo-
tactic. In gastric cancer, hepatic metastasis was reported to be
frequent in types 1 and 2 macroscopically, tubular type and poorly
differentiated and solid type histologically, and medullary type of
tumour stroma (Kito et al, 1981). As indicated in this study,
dThdPase protein levels were increased in these types. Further
investigation will be needed to clarify the role of dThdPase on
hepatic metastasis in gastric cancer.
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